A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...

As our knowledge about aromatase inhibitors and their side effects has expanded, questions remain unanswered with regards to their influence on cognition. Future study designs evaluating cognitive ...

Tyrosine (Tyr) phosphorylation of p27 by Abl and Src family kinases reduces p27–CDK2 inhibition and transforms p27 from inhibitor to substrate of cyclin–CDK2 complexes. p27 phosphorylation at ...

These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...

Unfortunately, one in 3–4 HA patients develop neutralizing anti-FVIII antibodies, clinically referred to as “inhibitors,” requiring the use of various “bypass” agents to prevent bleeding and to manage ...